Cepheid (CPHD) is Reiterated by Canaccord Genuity to Hold, Raises Price Target to $ 34

Cepheid (CPHD) was Reiterated by Canaccord Genuity to “Hold” according to the research note released today. The brokerage firm has raised the Price Target to $ 34 from a previous price target of $29 . Canaccord Genuity advised their investors in a research report released on Apr 14, 2016.

Many Wall Street Analysts have commented on Cepheid. Shares were Reiterated by Canaccord Genuity on Feb 3, 2016 to “Hold” and Lowered the Price Target to $ 29 from a previous price target of $34 .Shares were Reiterated by Barclays on Feb 3, 2016 to “Equal Weight” and Lowered the Price Target to $ 36 from a previous price target of $38 .

On the company’s financial health, Cepheid reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.02. The company had revenue of $147.00 million for the quarter, compared to analysts expectations of $147.01 million. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.

Cepheid closed down -1.06 points or -3.04% at $33.76 with 7,83,573 shares getting traded on Monday. Post opening the session at $35.01, the shares hit an intraday low of $33.62 and an intraday high of $35.19 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Mar 11, 2016, Peter V. Farrell (EVP, Worldwide Commercial Ops) sold 393 shares at $33.01 per share price. According to the SEC, on Mar 2, 2016, Robert J Easton (director) sold 12,500 shares at $31.13 per share price. On Feb 9, 2016, Warren C Jr Kocmond (EVP & Chief Operating Officer) sold 292 shares at $28.53 per share price, according to the Form-4 filing with the securities and exchange commission.

Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.


Leave a Reply

Cepheid - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cepheid. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.